CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0000509: ConjunctivitisHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug776 Normobaric oxygen therapy Wiki 0.71
drug551 Hyperbaric oxygen therapy Wiki 0.71
drug1017 Schirmer Test I Wiki 0.71
drug554 IC14 Wiki 0.71
drug850 Placebo Wiki 0.06

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003231 Conjunctivitis NIH 1.00
D015817 Eye Infections NIH 0.71
D007249 Inflammation NIH 0.22
D014777 Virus Diseases NIH 0.10

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Tear Fluid miRNA Analysis in Sars-Cov2 Conjunctivitis

The aim of this study is to assess the virus RNA, and miRNA levels related to viral infection, and inflammatory response in tears of hospitalized patients with a diagnosis of COVID-19 with and without conjunctivitis and to correlate them with clinical condition. Tears will be collected by using Schirmer Test I, a non invasive painless test which can be performed at the patient's bed. Tears will be collected on the graduated paper strips pulling the lower lid gently downward for 5 minutes. Following, the strip will be placed in a 2.0 mL Eppendorf tube and stored at −80◦C (or - 20°C)

NCT04346160 COVID Conjunctivitis Diagnostic Test: Schirmer Test I
MeSH:Conjunctivitis
HPO:Conjunctivitis

Primary Outcomes

Description: - to asses virus RNA and miRNA levels in tears

Measure: virus molecular analysis

Time: 2 weeks

Description: - to asses inflammatory response molecules

Measure: host molecular analysis

Time: 2 weeks

Secondary Outcomes

Description: To analyze the prevalence of conjunctivitis in patients with a diagnosis of COVID-19 and the assessment of the predictive value of conjunctivitis in the development of the COVID-19 disease (or in developing respiratory distress forms-ARDS).

Measure: Epidemiologic data

Time: 2 weeks

2 Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting With Conjunctivitis to the Ophthalmology Clinics During the COVID-19 Pandemic

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified, highly contagious RNA virus causing respiratory infectious disease, Coronavirus Disease 2019 (COVID-19). Conjunctivitis has been reported as a rare finding of the disease, and preliminary studies showed that the virus RNA could be detected in ocular secretions using polymerase chain reaction (PCR) assays when conjunctivitis present. This study aims to estimate the proportion of SARS-CoV-2 associated conjunctivitis among patients with suspected viral conjunctivitis presented to the ophthalmology clinics of Wilmer Eye Institute during the COVID-19 pandemic. The investigators also aim to identify whether SARS-CoV-2 associated conjunctivitis is an isolated finding or an early sign of COVID-19.

NCT04374656 Conjunctivitis SARS-CoV-2 COVID-19 Ocular Infection, Viral Ocular Inflammation
MeSH:Eye Infections Eye Infections, Viral Conjunctivitis Inflammation Virus Diseases
HPO:Conjunctivitis

Primary Outcomes

Description: Number of conjunctival samples with positive PCR divided by the total number of conjunctival samples

Measure: Proportion of conjunctival samples tested positive for SARS-CoV-2

Time: 1 year

Secondary Outcomes

Description: Number of nasal samples with positive PCR divided by the number of conjunctival samples with positive PCR

Measure: Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples

Time: 1 year

Description: Number of nasopharyngeal samples with positive PCR divided by the number of conjunctival samples with positive PCR

Measure: Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples

Time: 1 year

Description: Number of patients developed COVID-19 divided by the number of the study population

Measure: Rate of development of COVID-19 in the study patient population

Time: 1 year

Description: Number of conjunctival samples with positive PCR divided by the number of patients developed COVID-19

Measure: Positive conjunctival sample rate in patient developed COVID-19

Time: 1 year


HPO Nodes